Challenges for lupus management in emerging countries

Presse Medicale

Volumn 43, Issue 6P2, 2014, Pages

  Tazi Mezalek, Zoubida ^a,b   Bono, Wafaa ^c  

^a MOHAMMED V UNIVERSITY   (Morocco)

^b IBN SINA HOSPITAL   (Morocco)

^c HASSAN II UNIVERSITY HOSPITAL   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ANTIMALARIAL AGENT; AZATHIOPRINE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE;

ADVERSE OUTCOME; CLINICAL FEATURE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; EDUCATIONAL STATUS; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DISPARITY; HUMAN; INCIDENCE; KIDNEY BIOPSY; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; PROGNOSIS; RISK FACTOR; SHORT SURVEY; SOCIAL STATUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; WORK DISABILITY; COST OF ILLNESS; DELAYED DIAGNOSIS; DISEASE EXACERBATION; EDUCATION PROGRAM; ETHNIC DIFFERENCE; HOSPITALIZATION; INFECTION; KIDNEY FAILURE; MEDICALLY UNDERSERVED; MEDICALLY UNINSURED; MEDICATION COMPLIANCE; ONSET AGE; QUALITY ADJUSTED LIFE YEAR; RACE DIFFERENCE; SEPSIS; SEX RATIO; SOCIOECONOMICS; SURVIVAL RATE;

DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICALLY UNDERSERVED AREA; OPPORTUNISTIC INFECTIONS; SOCIAL CLASS; TREATMENT OUTCOME;

EID: 84902546789     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.04.002     Document Type: Short Survey

References (105)

1. Lateef A., Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012, 14:S4.
2. Danchenko N., Satia J.A., Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006, 15:308-318.
3. Alarcon G.S., Friedman A.W., Straaton K.V., Moulds J.M., Lisse J., Bastian H.M., et al. Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999, 8:197-209.
4. Gonzalez L.A., Toloza S.M.A., McGwin G., Alarcon G.S. Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. Lupus 2013, 22:1214-1224.
5. Ghosh R., Datta A., Lahiri K. International O.R. Healthcare in emerging countries. Challenges and opportunities for operations research. ORMS-Today 2013, [Access 11/04/2014]. http://www.informs.org/ORMS-Today/Public-Articles/April-Volume-40-Number-2/International-O.R.-Healthcare-in-emerging-countries.
6. Pons-Estel B.A., Catoggio L.J., Cardiel M.H., Gentiletti S., Villa A.R., Abadi I., et al. The GLADEL multinational Latin American prospective inception cohort of 1214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among 'Hispanics'. Medicine 2004, 83:1-17.
7. Cervera R., Khamashta M.A., Hughes G.R. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009, 18:869-874.
8. Fangtham M., Petri M. 2013 update: Hopkins Lupus Cohort. Curr Rheumatol Rep 2013, 15:360.
9. Peschken C.A., Katz S.J., Silverman E., Pope J.E., Fortin P.R., Pineau C., et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol 2009, 36:1200-1208.
10. Patel M., Clarke A.M., Bruce I.N., Symmons D.P. The prevalence and incidence of biopsy proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum 2006, 54:2963-2969.
11. Kaslow R.A. High rate of death caused by systemic lupus erythematosus among US residents of Asian descent. Arthritis Rheum 1982, 25:414-418.
12. Bae S.C., Fraser P., Liang M.H. The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the prevalence gradient hypothesis. Arthritis Rheum 1998, 41:2091-2099.
13. Anstey N.M., Bastian I., Dunckley H., Currie B.J. Systemic lupus erythematosus in Australian aborigines: high prevalence, morbidity and mortality. Aust N Z J Med 1993, 23:646-651.
14. Tiffin N., Hodgkinson B., Okpechi I. Lupus in Africa: can we dispel the myths and face the challenges?. Lupus 2014, 23:102-111.
15. Alarcon G.S., McGwin G., Bastian H.M., Roseman J., Lisse J., Fessler B.J., et al. VII [correction of VIIII]. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 2001, 45:191-202.
16. Pamuk O.N., Akbay F.G., Dönmez S., Yilmaz N., Calayir G.B., Yavuz S. The clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: report from two centers. Lupus 2013, 22:1416-1424.
17. Flower C., Hennis Anselm J.M., Hambleton I.R., Nicholson G.D., Liang M.H., The Barbados National Registry, et al. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res 2012, 64:1151-1158.
18. Wadee S., Tikly M., Hopley M. Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology (Oxford) 2007, 46:1487-1491.
19. Mok C.C., Lau C.S. Lupus in Hong Kong Chinese. Lupus 2003, 12:717-722.
20. Li M., Zhang W., Leng X., Li Z., Ye Z., Li C., et al. Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus 2013, 22:1192-1199.
21. Rabbani M.A., Siddiqui B.K., Tahir M.H., Ahmad B., Shamim A., Shah S.M., et al. Systemic lupus erythematosus in Pakistan. Lupus 2004, 13:820-825.
22. Villamin C.A., Navarra S.V. Clinical manifestations and clinical syndromes of Filipino patients with systemic lupus erythematosus. Mod Rheumatol 2008, 18:161-164.
23. Borba E.F., Araujo D.B., Bonfa E., Shinjo S.K. Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus 2013, 22:744-749.
24. Al Arfaj A.S., Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 2009, 18:465-473.
25. Khanfir M.S., Houman M.H., Cherif E., Hamzaoui A., Souissi S., Ben Ghorbel I., et al. TULUP (TUnisian LUPus): a multicentric study of systemic lupus erythematosus in Tunisia. Int J Rheum Dis 2013, 16:539-546.
26. Fernandez M., Alarcon G.S., Calvo-Alen J., Andrade R., McGwin G., Vilá L.M., et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007, 57:576-584.
27. Alarcon G.S., McGwin G., Bartolucci A.A., Roseman J., Lisse J., Fessler B.J., et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001, 44:2797-2806.
28. Alarcon G.S., McGwin G., Petri M., Ramsey-Goldman R., Fessler B.J., Vilá L.M., et al. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med 2006, 3:e396.
29. Burgos P.I., McGwin G., Pons-Estel G.J., Reveille J.D., Alarcón G.S., Vilá L.M. US patients of Hispanic and African ancestries develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis 2011, 70:393-394.
30. Bastian H.M., Roseman J.M., McGwin G., Alarcón G.S., Friedman A.W., Fessler B.J., et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002, 11:152-160.
31. Mok C.C., Mak A., Chu W.P., To C.H., Wong S.N. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age groups. Medicine (Baltimore) 2005, 84:218-224.
32. Nazarinia M.A., Ghaffarpasand F., Shamsdin A., Karimi A.A., Abbasi N., Amiri A. Systemic lupus erythematosus in the Fars Province of Iran. Lupus 2008, 17:221-227.
33. Shayakul C., Ong-aj-yooth L., Chirawong P., Nimmannit S., Parichatikanond P., Laohapand T., et al. Lupus nephritis in Thailand: clinicopathologic findings and outcome in 569 patients. Am J Kidney Dis 1995, 26:300-307.
34. Rasulov U.R. Systemic lupus erythematosus in the native inhabitants of Tadzhikistan. Ter Arkh 1990, 62:90-94.
35. Walsh S.J., Algert C., Gregorio D.I., Reisine S.T., Rothfield N.F. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 1995, 22:1663-1668.
36. Taylor H.G., Stein C.M. Systemic lupus erythematosus in Zimbabwe. Ann Rheum Dis 1986, 45:645-648.
37. Mok C.C., Tang S.S., To C.H., Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005, 52:2774-2782.
38. Molina J.F., Gutierrez-Urena S., Molina J., Uribe O., Richards S., De Ceulaer C., et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997, 24:291-296.
39. Kasitanon N., Magder L.S., Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006, 85:147-156.
40. Ward M.M., Pyun E., Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum 1995, 38:274-283.
41. Duran S., Apte M., Alarcon G.S., for the LUMINA study group Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. J Nat Med Assoc 2007, 99:1196-1198.
42. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
43. Petri M., Orbai A.M., Alarcón G.S., Gordon C., Merrill J.T., Fortin P.R., et al. Derivation and validation of Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64:2677-2686.
44. Esdaile J.M., Joseph L., MacKenzie T., Kashgarian M., Hayslett J.P. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994, 21:2046-2051.
45. Faurschou M., Starklint H., Halberg P., Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006, 33:1563-1569.
46. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 2003, 82:299-308.
47. Petri M.A., Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. J Rheumatol 1992, 19:1559-1565.
48. Goldblatt F., Chambers S., Rahman A., Isenberg D.A. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009, 18:682-689.
49. Iriya S.M., Capelozzi V.L., Calich I., Martins M.A., Lichtenstein A. Causes of death in patients with systemic lupus erythematosus in Sao Paulo, Brazil: a study of 113 autopsies. Arch Intern Med 2001, 161:1557.
50. Navarra S.V., King J.O. An overview of clinical manifestations and survival of systemic lupus erythematosus in Asia. APLAR J Rheumatol 2006, 9:336-341.
51. Jeong S.J., Choi H., Lee H.S., Han S.H., Chin B.S., Baek J.H., et al. Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis 2009, 41:268-274.
52. Erdozain J.G., Ruiz-Irastorza G., Egurbide M.V., Martinez- Berriotxoa A., Aguirre C. High risk of tuberculosis in systemic lupus erythematosus?. Lupus 2006, 15:232-235.
53. Hodkinson B., Musenge E., Tikly M. Osteoarticular tuberculosis in patients with systemic lupus erythematosus. QJM 2009, 102:321-328.
54. Yun J.E., Lee S.W., Kim T.H., Jun J.B., Jung S., Bae S.C., et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 2002, 20:127-132.
55. Sayarlioglu M., Inanc M., Kamali S., Cefle A., Karaman O., Gul A., et al. Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 2004, 13:274-278.
56. Victorio-Navarra S.T., Dy E.E., Arroyo C.G., Torralba T.P. Tuberculosis among Filipino patients with systemic lupus erythematosus. Semin Arthritis Rheum 1996, 26:628-634.
57. Gould T., Tikly M. Systemic lupus erythematosus in a patient with human immunodeficiency virus infection - challenges in diagnosis and management. Clin Rheumatol 2004, 23:166-169.
58. Pons-Estel G.J., Alarcón G.S., Hachuel L., Boggio G., Wojdyla D., Pascual-Ramos V., et al. Antimalarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin American cohort. Rheumatology (Oxford) 2012, 51:1293-1298.
59. Shinjo S.K., Bonfá E., Wojdyla D., Borba E.F., Ramirez L.A., Scherbarth H.R., et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010, 62:855-862.
60. Walsh M., James M., Jayne D., Tonelli M., Manns B.J., Hemmelgarn B.R. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007, 2:968-975.
61. Mak A., Cheak A.A., Tan J.Y., Su H.C., Ho R.C., Lau C.S. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 2009, 48:944-952.
62. Isenberg D., Appel G.B., Contreras G., Dooley M.A., Ginzler E.M., Jayne D., et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010, 49:128-140.
63. Walsh M., Solomons N., Lisk L., Jayne D.R.W. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 2013, 61:710-715.
64. Tse K.C., Tang C.S., Lam M.F., Yap D.Y., Chan T.M. Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis. J Rheumatol 2009, 36:76-81.
65. Wilson E.C., Jayne D.R., Dellow E., Fordham R.J. The cost-effectiveness of mycophenolate mofetil as first-line therapy in active lupus nephritis. Rheumatology (Oxford) 2007, 46:1096-1101.
66. Chambers S., Raine R., Rahman A., Hagley K., Ceulaer K.D., Isenberg D. Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus in Jamaica. Lupus 2008, 17:761-769.
67. Garcia Popa-Lisseanu M.G., Greisinger A., Richardson M., O'Malley K.J., Janssen N.M., Marcus D.M., et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol 2005, 32:913-919.
68. Petri M., Perez-Gutthann S., Longenecker J.C., Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991, 91:345-353.
69. Rojas-Serrano J., Cardiel M.H. Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 2000, 8:601-606.
70. Koneru S., Kocharla L., Higgins G.C., Ware A., Passo M.H., Farhey Y.D., et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 2008, 14:195-201.
71. Garcia-Gonzales A., Richardson M., Garcia Popa-Lisseanu M., Cox V., Kallen M.A., Janssen N., et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2008, 27:883-889.
72. Oliveira-Santos M., Verani J.F.S., Klumb E.M., Albuquerque E.M.N. Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus 2011, 20:320-329.
73. Slawsky K.A., Fernandes A.W., Fusfeld L., Manzi S., Goss T.F. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res (Hoboken) 2011, 63:1224-1232.
74. Zhu T.Y., Tam L.S., Li E.K. Cost of illness studies in systemic lupus erythematosus: a systemic review. Arthristis Care Res 2011, 63:751-760.
75. Clarke A.E., Petri M., Manzi S., Isenberg D.A., Gordon C., Senécal J.L., et al. The systemic lupus erythematosus Tri-nation study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) 2004, 43:1016-1024.
76. Sutcliffe N., Clarke A.E., Taylor R., Frost C., Isenberg D.A. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001, 40:37-47.
77. Huscher D., Merkesdal S., Thiele K., Zeidler H., Schneider M., Zink A., et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006, 5:1175-1183.
78. Zhu T., Tam L., Lee V.W., Lee K.K., Li E.K. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009, 61:1159-1167.
79. Aghdassi E., Zhang W., St-Pierre Y., Clarke A.E., Morrison S., Peeva V., et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol 2011, 38:658-666.
80. Clarke A.E., Panopalis P., Petri M., Manzi S., Isenberg D.A., Gordon C., et al. SLE patients with renal damage incur higher health care costs. Rheumatology 2008, 47:329-333.
81. Panopalis P., Petri M., Manzi S., Isenberg D.A., Gordon C., Senécal J.L., et al. The systemic lupus erythematosus Tri-nation study: cumulative indirect costs. Arthritis Rheum 2007, 57:64-70.
82. Clarke A.E., Esdaile J.M., Bloch D.A., Lacaille D., Danoff D.S., Fries J.F. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993, 36:1548-1559.
83. Campbell R., Cooper G., Gilkeson G.S. The impact of systemic lupus erythematosus on employment. J Rheumatol 2009, 36:2470-2475.
84. Partridge A.J., Karlson E.W., Daltroy L.H., Lew R.A., Wright E.A., Fossel A.H., et al. Risk factors for early work disability in systemic lupus erythematosus: results from a multicenter study. Arthritis Rheum 1997, 40:2199-2206.
85. Mok C.C., Cheung M.Y., Ho L.Y., Yu K.L., To C.H. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus 2008, 17:1103-1107.
86. Bertoli A.M., Fernandez M., Alarcon G.S., Vila L.M., Reveille J.D. Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability. Ann Rheum Dis 2007, 66:12-17.
87. Panopalis P., Yazdany J., Gillis J.Z., Julian L., Trupin L., Hersh A.O., et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008, 59:1788-1795.
88. Zheng Y., Ye D.Q., Pan H.F., Li W.X., Li L.H., Li J., et al. Influence of social support on health-related quality of life in patients with systemic lupus erythematosus. Clin Rheumatol 2009, 28:265-269.
89. Li B.Z., Pan H.F., Ye D.Q. A bibliometric study of literature on SLE research in PubMed (2002-2011). Lupus 2013, 22:772-777.
90. Lu L.J., Wallace D.J., Navarra S.V., Weisman M.H. Lupus registries: evolution and challenges. Semin Arthritis Rheum 2010, 39:224-245.
91. Cook N.L., Ayanian J.Z., Orav E.J., Hicks L.S. Differences in specialist consultations for cardiovascular disease by race, ethnicity, gender, insurance status, and site of primary care. Circulation 2009, 119:2463-2470.
92. van Assen S., Agmon-Levin N., Elkayam O., Cervera R., Doran M.F., Dougados M., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.
93. Gaitonde S., Pathan E., Sule A., Mittal G., Joshi V.R. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long-term steroid treatment. Ann Rheum Dis 2002, 61:251-253.
94. Vernon A. Treatment of latent tuberculosis infection. Semin Respir Crit Care Med 2013, 34:67-86.
95. Bertsias G., Ioannidis J.P., Boletis J., Aringer M., Bajema I., Berden J.H., et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR Standing Committee for International Clinical Studies including Therapeutics. Ann Rheum Dis 2008, 67:195-205.
96. Hahn B.H., McMahon M.A., Wilkinson A., Wallace W.D., Daikh D.I., Fitzgerald J.D., et al. American College of Rheumatology guidelines for screening, treatment and management of lupus nephritis. Arthritis Care Res 2012, 64:797-808.
97. Bertsias G.K., Tektonidou M., Amoura Z., Aringer M., Bajema I., Berden J.H., et al. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012, 71:1771-1782.
98. Ben-Zvi I., Kivity S., Langevitz P., Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012, 42:145-153.
99. WHO Adherence to long-term therapies: evidence for action 2003, [Access 11/04/2014]. http://www.whoint/chp/knowledge/publications/adherence_full_reportpdf.
100. Drenkard C., Dunlop-Thomas C., Easley K., Bao G., Brady T., Lim S.S. Benefits of a self-management program in low-income African-American women with systemic lupus erythematosus: results of a pilot test. Lupus 2012, 21:1586-1593.
101. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Aymard G., Leroux G., Marra D., et al. Very low blood hydroxychloroquine concentrations as an objective marker of poor adherence to treatment in systemic lupus erythematosus. Ann Rheum Dis 2007, 66:821-824.
102. Ting T.V., Kudalkar D., Nelson S., Cortina S., Pendl J., Budhani S., et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 2012, 39:174-179.
103. Mosca M., Boumpas D., Bruce I.N., Cervera R., Czirjak L., Dörner T., et al. Treat-to-target in systemic lupus erythematosus: where are we today?. Clin Exp Rheumatol 2012, 30(Suppl. 73):S112-S115.
104. Vaczy E., Seaman B., Peterson-Sweeney K., Hondorf C. Passport to health: an innovative tool to enhance healthy lifestyle choices. J Pediatr Health Care 2011, 25:31-37.
105. Haideri N.A., Moormeier J.A. Impact of patient navigation from diagnosis to treatment in an urban safety net breast cancer population. J Cancer 2011, 2:467-473.